Drug
Apixaban clinical trials
Also written Eliquis, BMS-562247 and BMS-562247-01.
How each study uses apixaban is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the apixaban studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 28 Dec 2012 · ELIQUIS · NDA 202155 (FDA, Drugs@FDA)
- European Union
- 18 May 2011 · Eliquis · EMEA/H/C/002148 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
180 studies that test it; most in 2026 (21)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 5 |
| 2013 | 4 |
| 2014 | 10 |
| 2015 | 12 |
| 2016 | 17 |
| 2017 | 15 |
| 2018 | 10 |
| 2019 | 8 |
| 2020 | 12 |
| 2021 | 19 |
| 2022 | 7 |
| 2023 | 7 |
| 2024 | 8 |
| 2025 | 9 |
| 2026 | 21 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 44 · Other 136
Bristol-Myers Squibb (26) · Pfizer (6) · Assistance Publique - Hôpitaux de Paris (5) · Ottawa Hospital Research Institute (5) · Northern Jiangsu People's Hospital (4) · Mayo Clinic (4) · Herlev and Gentofte Hospital (2) · Combined military hospital lahore (2)
Often tested with
Tested in the same studies.
Rivaroxaban (33) · Edoxaban (15) · Dabigatran (13) · Warfarin (11) · Enoxaparin (5) · Dalteparin (5) · Aspirin (3) · PRT064445 (2)
Related medicines
As reviewed, each with the page that says it.
- One of Factor Xa inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 4 phase 3 studies under way
Apixaban is the comparator. A study of two new drugs counts under both.
- 3Cenvacibart · Regeneron Pharmaceuticals · next primary completion Feb 2027
- 1Milvexian · Janssen Research & Development, LLC · next primary completion Dec 2026
Reaching primary completion within a year · 18, 2 in phase 3
Studies that test apixaban, phase 3 first.
- Apr 2027Anticoagulation in ICH Survivors for Stroke Prevention and RecoveryPhase 3 · Yale University
- Jun 2027The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery TrialPhase 3 · Population Health Research Institute
- Dec 2026Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver CirrhosisPhase 1 · Insel Gruppe AG, University Hospital Bern
- Dec 2026Venous Thromboembolism Prevention in Outpatients With GliomaPhase 2 · University of Vermont Medical Center
- Mar 2027The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)Phase 4 · Herlev and Gentofte Hospital
- Apr 2027Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism ProphylaxisNot applicable · Ron Beloosesky MD
- Apr 2027Apixaban-PK Trial: Preventing Portal Hypertension Complications in CirrhosisPhase 4 · Asian Institute Of Medical Sciences
- Apr 2027Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee ArthroplastyNot applicable · Military Hospital of Tunis
- Jun 2027THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)Phase 4 · Imperial College London
- Jul 2027Apixaban in ThrombocytopeniaEarly Phase 1 · Rushad Patell
Studies
Open first, then newest update. How each study uses apixaban is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 180
- SWITCH: Apixaban vs Vitamin K in HM3RecruitingPhase 3Columbia UniversityNCT07471139Written as Apixaban
- Oral Anticoagulation in Patients With Prior Deep Intracerebral Hemorrhage, Atrial Fibrillation, and Ischemic StrokeNot yet recruitingPhase 4Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07609654Written as Apixaban
- BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral AtherosclerosisRecruitingPhase 4Yonsei UniversityNCT07237308Written as Apixaban
- Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee ArthroplastyRecruitingNot applicableMilitary Hospital of TunisNCT07869615Written as Apixaban
- Vortosiran in Atrial FibrillationNot yet recruitingPhase 2Ribocure Pharmaceuticals ABNCT07870889Written as Apixaban
- Edoxaban Versus Apixaban in Cancer-Associated Venous ThromboembolismNot yet recruitingPhase 4Samsung Medical CenterNCT07852637Written as Apixaban
- COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial FibrillationRecruitingPhase 4Ottawa Hospital Research InstituteNCT04642430Written as Apixaban
- Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer TreatmentRecruitingPhase 3University of BirminghamNCT07160686Written as Apixaban
- Comparing the Safety and Efficacy of Apixaban and RivaroxabanRecruitingPhase 4VA Office of Research and DevelopmentNCT06953726Written as Apixaban
- Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple MyelomaRecruitingNot applicableCentre Hospitalier Universitaire de Saint EtienneNCT06474182Written as Apixaban
- The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery TrialRecruitingPhase 3Population Health Research InstituteNCT04284839Written as DOAC
- Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord InjuryRecruitingNot applicableLoewenstein HospitalNCT05484557Written as Apixaban
- Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis 2 (SAFE-D2)Not yet recruitingPhase 3Unity Health TorontoNCT07779746Written as Eliquis
- Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver CirrhosisRecruitingPhase 1Insel Gruppe AG, University Hospital BernNCT04874428Written as Apixaban 2.5 mg Oral Tablet
- Apixaban to Prevent Decompensation of Early Liver Cirrhosis TrialNot yet recruitingPhase 3University College, LondonNCT07726693Written as Apixaban 2.5 mg twice daily
- Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism ProphylaxisNot yet recruitingNot applicableRon Beloosesky MDNCT07716332Written as Apixaban
- Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic DiseaseNot yet recruitingPhase 4James BayleyNCT07713875Written as Apixaban
- Apixaban Versus Warfarin for Left Ventricular ThrombusRecruitingPhase 3University of ArizonaNCT07709780Written as Apixaban
- Thromboprophylaxis in Lower Limb ImmobilisationRecruitingPhase 3Queen Mary University of LondonNCT06370273Written as Apixaban
- Stroke Prevention In Ischemic Stroke With Covert Atrial FibrillationRecruitingPhase 4Assistance Publique - Hôpitaux de ParisNCT06486792Written as Apixaban
See all 180 studies that test apixaban →
Given beside what is tested · 10 — apixaban is usual care or a partner of the new treatment
- to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and ApixabanRecruitingPhase 1Onconic Therapeutics Inc.NCT07265466Written as JP-1366 and apixaban
- A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy SubjectsCompletedPhase 1Lumosa Therapeutics Co., Ltd.NCT04809818Written as Apixaban
- Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCTCompletedPhase 2Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.NCT03288454Written as Apixaban
- Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)CompletedPhase 2Portola PharmaceuticalsNCT01758432Written as PRT064445/Apixaban
- Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older SubjectsCompletedPhase 1VarmX B.V.NCT05152420Written as Apixaban
- A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian SubjectsCompletedPhase 2Portola PharmaceuticalsNCT03310021Written as Apixaban
- Apixaban Versus Warfarin in Patients With Left Ventricular (LV) ThrombusCompletedPhase 3Hadassah Medical OrganizationNCT03232398Written as Apixaban Oral Tablet [Eliquis]
- Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary EmbolismTerminatedPhase 4Victor Tapson, MDNCT03988842Written as Apixaban
- Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate KcentraCompletedPhase 1Thomas Jefferson UniversityNCT02270918Written as Apixaban
- A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult SubjectsCompletedPhase 1Bristol-Myers SquibbNCT02074358Written as Apixaban
As the comparator · 18 — what is tested is compared with apixaban
- REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in AdultsRecruitingPhase 3Regeneron PharmaceuticalsNCT07015905Written as Apixaban
- Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic CancersRecruitingPhase 3Regeneron PharmaceuticalsNCT07493304Written as Apixaban
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationRecruitingPhase 3Regeneron PharmaceuticalsNCT07626411Written as Apixaban
- Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationRecruitingPhase 2Regeneron PharmaceuticalsNCT07175428Written as Apixaban
- Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus BacteremiaRecruitingPhase 4McGill University Health Centre/Research Institute of the McGill University Health CentreNCT06650501Written as Apixaban
- Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery DiseaseRecruitingPhase 4Samsung Medical CenterNCT07753200Written as Apixaban
- A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationActive, not recruitingPhase 3Janssen Research & Development, LLCNCT05757869Written as Apixaban
- A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTETerminatedPhase 3Anthos Therapeutics, Inc.NCT05171049Written as Apixaban
- Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical TherapyCompletedPhase 4Charite University, Berlin, GermanyNCT03463317Written as Apixaban
- A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult ParticipantsCompletedPhase 2Regeneron PharmaceuticalsNCT05618808Written as Apixiban
- Pivotal BE Study of TAH3311 ODF vs ELIQUIS® Tablet Under Fasted Condition in Healthy VolunteersCompletedPhase 2TAHO Pharmaceuticals Ltd.NCT06689436Written as 5 mg Apixaban Oral Tablet (US RS/RLD)
- A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for StrokeTerminatedPhase 3BayerNCT05643573Written as Apixaban
- Strategies for the Management of Atrial Fibrillation in patiEnts Receiving DialysisCompletedPhase 2Unity Health TorontoNCT03987711Written as Apixaban
- Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.CompletedPhase 2BayerNCT04218266Written as Apixaban
- Efficacy and Safety of MAA868 in Patients With Atrial FibrillationWithdrawnPhase 2Novartis PharmaceuticalsNCT03398434Written as Apixaban
- FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee ArthroplastyCompletedPhase 2BayerNCT03276143Written as Apixaban
- Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial FibrillationStatus unknownNot applicableYonsei UniversityNCT02633774Written as Apixaban
- Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)CompletedPhase 3Bristol-Myers SquibbNCT00423319Written as Apixaban
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting2
- SWITCH: Apixaban vs Vitamin K in HM3Nov 4, 2026NCT07471139
- BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral AtherosclerosisOct 16, 2026NCT07237308
Codes
What other systems call apixaban · ClinicalTrials.gg INT005142
- MeSH (NLM) C522181apixabanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 3Z9Y7UWC1JAPIXABANConfirmed FDA, NLM, Wikidata
- RxNorm 1364430Confirmed FDA, Wikidata
- Wikidata Q414462apixabanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61308ApixabanOne source FDA
- DrugBank DB06605One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C522181 | apixaban | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 3Z9Y7UWC1J | APIXABAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1364430 | — | Confirmed FDA, Wikidata |
| Wikidata | Q414462 | apixaban | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61308 | Apixaban | One source FDA |
| DrugBank | DB06605 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.